ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025
Blautia luti reduces neratinib-induced diarrhea in a rat model.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeNeratinib is a pan-human epidermal growth factor receptor (HER) tyrosine kinase inhibitor (TKI) used in the treatment of HER2+ breast cancer. Diarrhea is the most commonly reported toxicity, with the majority experiencing at least some grade of diarrhea. The mechanisms behind neratinib-induced diarrhea are yet to be fully defined, but have been linked to gut microbiome changes, specifically decreased levels of the genera Blautia. This study aimed to investigate the efficacy of Blautia luti (B.luti) administered as a daily probiotic on neratinib-induced diarrhea, and its effects on the gut microbiome in a well-established rat model.
methodsFemale albino Wistar (AW) rats (n = 40) were randomly allocated to groups including; vehicle control (VC), neratinib alone, B.luti alone and neratinib + B.luti in different schedules (Pre, Pre & Post or Post). Daily oral gavage administration of B.luti (10
resultsGrade 3 diarrhea was reduced in the Post group when compared to the neratinib alone group (p = 0.0122). No significant differences were seen in the tissue injury scores of the ileum or colon. There was no significant change in microbial composition with B.luti administration.
conclusionThis study demonstrated that administration of B.luti supplementation, was effective in reducing neratinib-induced diarrhea severity when consumed concurrently. This administration schedule may have a protective role in the intestines through immunomodulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.